{"id":495768,"date":"2020-07-14T11:32:01","date_gmt":"2020-07-14T11:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=495768"},"modified":"2020-07-14T11:32:01","modified_gmt":"2020-07-14T11:32:01","slug":"graft-versus-host-disease-gvhd-market-analysis-market-size-epidemiology-companies-drugs-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/graft-versus-host-disease-gvhd-market-analysis-market-size-epidemiology-companies-drugs-and-competitive-analysis-by-delveinsight_495768.html","title":{"rendered":"Graft versus host disease (GVHD) Market Analysis, Market Size, Epidemiology, Companies, Drugs and Competitive Analysis by DelveInsight"},"content":{"rendered":"
\"Graft<\/a><\/p>\n
\n
“Graft versus host disease (GVHD)- Market Insight, Epidemiology and Market Forecast -2030\u201d<\/div>\n<\/div>\n<\/div>\n

DelveInsight has launched a new report on “Graft versus host disease (GVHD)- Market Insight, Epidemiology and Market Forecast -2030<\/strong>”.<\/p>\n

 <\/p>\n

DelveInsight’s “Graft versus host disease (GVHD) – Market Insights, Epidemiology, and Market Forecast-2030<\/a>“<\/strong> report delivers an in-depth understanding of the Graft versus host disease (GVHD), historical and forecasted epidemiology as well as the Graft versus host disease (GVHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

 <\/strong><\/p>\n

Some facts of the report:<\/strong><\/p>\n

    \n
  1. Based on DelveInsight’s analysis, total allogeneic HSCTs cases accounts for approximately 41.08% of total HSCTs cases, as there were XX allogeneic incident cases diagnosed in 2017, XX of which were first allogeneic HSCT (i.e., 84.83% of total allogeneic cases)..<\/li>\n
  2. Among the EU5 countries, Germany has the highest HSCTs cases followed by France and Italy.<\/li>\n
  3. DelveInsight estimates higher incidence of HSCTs in the United States among 7MM.<\/li>\n<\/ol>\n

     <\/p>\n

    Key Benefits of the Report:<\/strong><\/p>\n

      \n
    1. Graft versus host disease (GVHD) Market report covers a descriptive overview and comprehensive insight of the Graft versus host disease (GVHD) epidemiology and Graft versus host disease (GVHD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/li>\n
    2. Graft versus host disease (GVHD) market report provides insights on the current and emerging therapies.<\/li>\n
    3. Graft versus host disease (GVHD) market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/li>\n
    4. Graft versus host disease (GVHD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Graft versus host disease (GVHD) market.<\/li>\n<\/ol>\n

       <\/strong><\/p>\n

      Request for Sample Page: https:\/\/www.delveinsight.com\/sample-request\/acute-pain-market<\/a><\/strong><\/p>\n

       <\/strong><\/p>\n

      Graft versus host disease (GvHD)<\/strong><\/a> is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD occurs when a particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.<\/p>\n

      GvHD has two types Acute GvHD and Chronic GvHD. Acute GvHD is also known as fulminant GVHD, and occurs usually in the initial 2-3 months after transplantation. While Chronic GVHD occurs around 3-4 months after the transplantation has happened, and has more diverse complications. This type affects liver, stomach, vagina, joints, lungs, gut, mouth and glands secreting mucous or saliva.<\/p>\n

      Acute GVHD is staged and graded (grade I-IV) by the number and extent of organ involvement. While Chronic GvHD is staged according to a new clinical scoring system on a four point scale (0-3) with 0 representing no involvement, 1 representing mild involvement (no significant impairment of daily living), 2 representing moderate involvement (significant impairment of daily living) and 3 representing severe impairment (major disability).<\/p>\n

       <\/em><\/strong><\/p>\n

      “According to Delveinsight, No significant difference was found in incidence of GvHD among male and female”<\/em><\/strong><\/p>\n

       <\/strong><\/p>\n

      Request for Sample Page: https:\/\/www.delveinsight.com\/sample-request\/acute-pain-market<\/a><\/strong><\/p>\n

       <\/strong><\/p>\n

      The launch of the emerging therapies is expected to significantly impact Graft versus host disease (GvHD)<\/strong> treatment scenario in the upcoming years:-<\/p>\n

      Drugs covered:<\/strong><\/p>\n